中华外科杂志
中華外科雜誌
중화외과잡지
CHINESE JOURNAL OF SURGERY
2008年
2期
132-135
,共4页
郭贵龙%杨光伦%李卓英%尤捷%杨凯%黄督平%胡孝渠%张筱骅
郭貴龍%楊光倫%李卓英%尤捷%楊凱%黃督平%鬍孝渠%張篠驊
곽귀룡%양광륜%리탁영%우첩%양개%황독평%호효거%장소화
乳腺肿瘤%前列腺素内过氧化物合酶%内皮生长因子%预后
乳腺腫瘤%前列腺素內過氧化物閤酶%內皮生長因子%預後
유선종류%전렬선소내과양화물합매%내피생장인자%예후
Breast neoplasms%Prostaglandin-endoperoxide synthase%Endothelial growth factors%Prognosis
目的 探讨环氧合酶-2(COX-2)对人乳腺癌淋巴管形成的影响.方法 1998年11月至2002年3月行手术治疗并经病理证实的乳腺癌患者94例,随访83例,失访11例.免疫组织化学方法 检测COX-2、血管内皮生长因子-C(VEGF-C)及D2-40在乳腺癌中的表达.逆转录聚合酶链式反应(RT-PCR)和Western印迹法分别检测加入不同浓度COX-2抑制剂尼美舒利后VEGF-C mRNA及蛋白的变化.Western印迹法检测加入外源性前列腺素E2(PGE2)和曲妥珠单抗后VEGF-C蛋白的变化.结果 46.8%的乳腺癌组织呈COX-2高表达,51.1%呈VEGF-C高表达.COX-2与VEGF-C(P<0.01)、淋巴管密度(P=0.032)和淋巴结转移(P=0.035)呈正相关,与乳腺癌患者的无病生存率(P=0.010)和总生存率(P=0.040)呈负相关.尼美舒利以剂量依赖性方式下调VEGF-C mRNA及蛋白表达,而PGE2上调其蛋白表达.曲妥珠单抗可显著降低VEGF-C的蛋白表达.结论 COX-2可通过上调VEGF-C的表达,促进乳腺癌的淋巴管形成和淋巴结转移,并影响乳腺癌患者的预后.
目的 探討環氧閤酶-2(COX-2)對人乳腺癌淋巴管形成的影響.方法 1998年11月至2002年3月行手術治療併經病理證實的乳腺癌患者94例,隨訪83例,失訪11例.免疫組織化學方法 檢測COX-2、血管內皮生長因子-C(VEGF-C)及D2-40在乳腺癌中的錶達.逆轉錄聚閤酶鏈式反應(RT-PCR)和Western印跡法分彆檢測加入不同濃度COX-2抑製劑尼美舒利後VEGF-C mRNA及蛋白的變化.Western印跡法檢測加入外源性前列腺素E2(PGE2)和麯妥珠單抗後VEGF-C蛋白的變化.結果 46.8%的乳腺癌組織呈COX-2高錶達,51.1%呈VEGF-C高錶達.COX-2與VEGF-C(P<0.01)、淋巴管密度(P=0.032)和淋巴結轉移(P=0.035)呈正相關,與乳腺癌患者的無病生存率(P=0.010)和總生存率(P=0.040)呈負相關.尼美舒利以劑量依賴性方式下調VEGF-C mRNA及蛋白錶達,而PGE2上調其蛋白錶達.麯妥珠單抗可顯著降低VEGF-C的蛋白錶達.結論 COX-2可通過上調VEGF-C的錶達,促進乳腺癌的淋巴管形成和淋巴結轉移,併影響乳腺癌患者的預後.
목적 탐토배양합매-2(COX-2)대인유선암림파관형성적영향.방법 1998년11월지2002년3월행수술치료병경병리증실적유선암환자94례,수방83례,실방11례.면역조직화학방법 검측COX-2、혈관내피생장인자-C(VEGF-C)급D2-40재유선암중적표체.역전록취합매련식반응(RT-PCR)화Western인적법분별검측가입불동농도COX-2억제제니미서리후VEGF-C mRNA급단백적변화.Western인적법검측가입외원성전렬선소E2(PGE2)화곡타주단항후VEGF-C단백적변화.결과 46.8%적유선암조직정COX-2고표체,51.1%정VEGF-C고표체.COX-2여VEGF-C(P<0.01)、림파관밀도(P=0.032)화림파결전이(P=0.035)정정상관,여유선암환자적무병생존솔(P=0.010)화총생존솔(P=0.040)정부상관.니미서리이제량의뢰성방식하조VEGF-C mRNA급단백표체,이PGE2상조기단백표체.곡타주단항가현저강저VEGF-C적단백표체.결론 COX-2가통과상조VEGF-C적표체,촉진유선암적림파관형성화림파결전이,병영향유선암환자적예후.
Objective To study the effect of cyclooxygenase-2(COX-2)on lymphangiogenasis in breast cancer.Methods By the means of immunohistochemistry,COX-2,vascular endothelial growth factor-C(VEGF-C)and D2-40 were examinated in the tissue samples of primary tumors from 94 patients underwent snrgical resections for breast cancer from November 1998 to March 2002.Eighty-three patients were followed-up.The expressions of VEGF-C mRNA and protein were detected by reverse transcription polymerase chain reaction(RT-PCR)and Western blot in MDA-MB-231 cell lines by the treatment of selective COX-2 inhibitor Nimesulide at different doses.The expressions of VEGF-C protein were evaluated in MDA-MB-231 cells treated by PGE2(1 μg/ml)and Trastuzumab(1 μg/ml),respectively.Results COX-2 over-expression was observed in 46.8%of surgical specimens(44/94),while VEGF-C overexpression occurred in 51.1%of tumor samples(48/94).COX-2 was strongly correlated with VEGF-C expression(P<0.01),microlymphatic vessels(P=0.032)and metastatic lymph nodes(P=0.035).Patients with COX-2 positive tumors had a significant shorter survival time than those with negative tumors did,including disease-free survival(P=0.010)and overall survival(P=0.040).Nimesulide could downregulate the expressions of VEGF-C mRNA and protein in a does-dependent manner,while PGE2 could upregulate the expressions.The expression of VEGF-C protein up-regulated by PGE2 treatment was decreased by Trastuzumab.Conclusions COX-2 over-expression can up-regulate the expression of VEGF-C.VEGF-C might promote lymph node metastasis by a lymphangiogenic pathway,then affect the prognosis of the patients with breast cancer.